热门资讯> 正文

MoonLake免疫治疗学GAAP每股收益为-0.84美元

2026-08-10 19:12

MoonLake Immunotherapeutics press release (MLTX): Q2 GAAP EPS of -$0.84.
MoonLake ended the second quarter with $537.0 million in cash, cash equivalents and short-term marketable debt securities and expects to have a cash runway to mid-2028; additionally, up to $400 million in non-dilutive funds remain available through its debt facility with Hercules Capital

More on MoonLake Immunotherapeutics

MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
MoonLake Immunotherapeutics: Label Upside Drives The Next Leg Higher
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow
MoonLake Immunotherapeutics prices $200M public offering of Class A shares
Stocks to watch on Monday after hours: MLTX, BBY, and DPZ

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。